Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom.
Haemato-Oncology Unit, The Royal Marsden Hospital, Sutton, United Kingdom.
Radiother Oncol. 2021 May;158:97-103. doi: 10.1016/j.radonc.2021.02.020. Epub 2021 Feb 23.
PURPOSE/OBJECTIVE: Total body irradiation (TBI) remains a key component of conditioning for allogeneic haemopoietic stem cell transplant (HSCT), with interstitial pneumonitis (IP) and chronic kidney disease (CKD) important late sequelae. We undertook a retrospective service evaluation of TBI patients treated with a forward-planned intensity modulated radiotherapy technique (FP IMRT).
MATERIAL/METHODS: 74 adult patients were identified; all received step and shoot FP IMRT TBI, 14.4 Gy in 8 fractions over 4 days. Mean doses to the lungs and kidneys were 12-12.5 Gy. Toxicities were defined as per CTCAE v4.0: IP as multilobar infiltrates on CT with symptoms of dyspnoea, and renal dysfunction as an Estimated Glomerular Filtration rate (eGFR) < 60 ml/min/1.73 m for > 3 months. Secondary endpoints were overall survival (OS), progression free survival (PFS), cumulative incidence of non-relapse mortality (NRM), relapse risk and of acute and chronic GvHD.
Patients received treatment for the following diagnosis: ALL/LBL (n = 37); AML (n = 33), CML-BC (n = 2) and High grade NHL (n = 2). The rate of IP due to any cause was 30%; positive microbiological evidence in 73% (16 /22). Idiopathic IP was seen in 8%, with only 4% (n = 3) having IP Grade ≥ 3. Two (4%) of 52 long term survivors developed CKD, one with thrombotic microangiopathy. 4 year NRM was 16% (CI 11-32%); no treatment related deaths in matched sibling or umbilical cord blood HSCT.
FP IMRT TBI, reducing dose to the lungs and kidneys, has lower rates of idiopathic IP and CKD compared to the literature. This technique is safe and effective conditioning for full intensity HSCT.
目的/目标:全身照射(TBI)仍然是异基因造血干细胞移植(HSCT)的重要条件,间质性肺炎(IP)和慢性肾脏病(CKD)是重要的晚期后遗症。我们对接受前瞻性计划调强放疗技术(FP IMRT)治疗的 TBI 患者进行了回顾性服务评估。
材料/方法:确定了 74 名成年患者;所有患者均接受分步射击 FP IMRT TBI,4 天内分 8 次给予 14.4Gy。肺和肾脏的平均剂量为 12-12.5Gy。毒性按 CTCAE v4.0 定义:IP 为 CT 上多灶性浸润,伴有呼吸困难症状,肾功能障碍为肾小球滤过率(eGFR)<60ml/min/1.73m 持续>3 个月。次要终点为总生存(OS)、无进展生存(PFS)、非复发死亡率(NRM)、复发风险以及急性和慢性移植物抗宿主病(GvHD)的累积发生率。
患者接受治疗的诊断如下:ALL/LBL(n=37);AML(n=33)、CML-BC(n=2)和高级别 NHL(n=2)。任何原因导致的 IP 发生率为 30%;有微生物学证据的为 73%(16/22)。特发性 IP 占 8%,仅 4%(n=3)的 IP 分级≥3。52 例长期幸存者中有 2 例(4%)发生 CKD,1 例合并血栓性微血管病。4 年 NRM 为 16%(CI 11-32%);在匹配的同胞或脐带血 HSCT 中无治疗相关死亡。
FP IMRT TBI 降低了肺和肾脏的剂量,与文献相比,特发性 IP 和 CKD 的发生率较低。该技术是全强度 HSCT 的安全有效的条件。